264 related articles for article (PubMed ID: 31721572)
1. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
[TBL] [Abstract][Full Text] [Related]
2. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
3. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
[TBL] [Abstract][Full Text] [Related]
4. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
5. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
[TBL] [Abstract][Full Text] [Related]
6. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
8. SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
Shomali M; Cheng J; Sun F; Koundinya M; Guo Z; Hebert AT; McManus J; Levit MN; Hoffmann D; Courjaud A; Arrebola R; Cao H; Pollard J; Lee JS; Besret L; Caron A; Bangari DS; Abecassis PY; Schio L; El-Ahmad Y; Halley F; Tabart M; Certal V; Thompson F; McCort G; Filoche-Rommé B; Cheng H; Garcia-Echeverria C; Debussche L; Bouaboula M
Mol Cancer Ther; 2021 Feb; 20(2):250-262. PubMed ID: 33310762
[TBL] [Abstract][Full Text] [Related]
9. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Xiong R; Zhao J; Gutgesell LM; Wang Y; Lee S; Karumudi B; Zhao H; Lu Y; Tonetti DA; Thatcher GR
J Med Chem; 2017 Feb; 60(4):1325-1342. PubMed ID: 28117994
[TBL] [Abstract][Full Text] [Related]
10. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
11. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
13. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
[TBL] [Abstract][Full Text] [Related]
14. Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
Scott JS; Moss TA; Balazs A; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Davey PRJ; Delpuech O; Fawell S; Fisher DI; Gagrica S; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Herlihy K; Hughes S; Hunt TA; Huynh H; Janbon SLM; Johnson T; Kavanagh S; Klinowska T; Lawson M; Lister AS; Marden S; McGinnity DF; Morrow CJ; Nissink JWM; O'Donovan DH; Peng B; Polanski R; Stead DS; Stokes S; Thakur K; Throner SR; Tucker MJ; Varnes J; Wang H; Wilson DM; Wu D; Wu Y; Yang B; Yang W
J Med Chem; 2020 Dec; 63(23):14530-14559. PubMed ID: 32910656
[TBL] [Abstract][Full Text] [Related]
15. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
Hu B; Hu J
Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
[TBL] [Abstract][Full Text] [Related]
16. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
Scott JS; Stead D; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Cureton N; Davey PRJ; Fisher DI; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Hughes SJ; Hunt TA; Johnson T; Kavanagh SL; Klinowska TCM; Larner CJB; Lawson M; Lister AS; Longmire D; Marden S; McGuire TM; McMillan C; McMurray L; Morrow CJ; Nissink JWM; Moss TA; O'Donovan DH; Polanski R; Stokes S; Thakur K; Trueman D; Truman C; Tucker MJ; Wang H; Whalley N; Wu D; Wu Y; Yang B; Yang W
J Med Chem; 2023 Feb; 66(4):2918-2945. PubMed ID: 36727211
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
Govek SP; Bonnefous C; Julien JD; Nagasawa JY; Kahraman M; Lai AG; Douglas KL; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
Bioorg Med Chem Lett; 2019 Feb; 29(3):367-372. PubMed ID: 30587451
[TBL] [Abstract][Full Text] [Related]
19. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
